As of 2025-10-21, the EV/EBITDA ratio of Aclaris Therapeutics Inc (ACRS) is -3.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Aclaris's latest enterprise value is 217.74 mil USD. Aclaris's TTM EBITDA according to its financial statements is -55.46 mil USD. Dividing these 2 quantities gives us the above Aclaris EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
Range | Selected | |
Trailing P/E multiples | 5.1x - 8.8x | 6.2x |
Forward P/E multiples | 7.7x - 12.8x | 9.8x |
Fair Price | (3.92) - (4.48) | (4.11) |
Upside | -295.1% - -323.1% | -304.4% |
Date | EV/EBITDA |